
|Articles|February 5, 2015
Accelovance Acquires European CRO
Accelovance, Inc. , a CRO therapeutically aligned in the areas of Oncology, Vaccines, and General Medicine; today announced it has acquired Altair Clinical, Ltd.
Advertisement
Accelovance, a therapeutically aligned CRO in the areas of oncology, vaccines, and general medicine; announced it has acquired Altair Clinical, a full service European clinical CRO and provider of global clinical CRO resourcing solutions to pharmaceutical, biotech, and medical device companies. The acquisition expands Accelovance's existing US and Beijing, China offices to include Cambridge, UK, Moscow, Russia, and staff located throughout Europe including Central and Eastern Europe (CEE) and the Middle East and North Africa (MENA).
Read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention
3
ACT Brief: AI-Driven Enrollment Results, Statistician Standards in Early Phase, and RNA Editing for Kidney Disease
4
SCOPE X: The COPD Case Study That Shows What AI Can Do for Enrollment
5




